KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Net Income (2016 - 2025)

Travere Therapeutics' Net Income history spans 15 years, with the latest figure at $24.7 million for Q4 2025.

  • For Q4 2025, Net Income rose 617775.0% year-over-year to $24.7 million; the TTM value through Dec 2025 reached $24.7 million, up 2801.09%, while the annual FY2025 figure was $24.7 million, 2801.09% up from the prior year.
  • Net Income reached $24.7 million in Q4 2025 per TVTX's latest filing, up from $4000.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $240.0 million in Q3 2023 to a low of -$88.8 million in Q4 2021.
  • Average Net Income over 5 years is $7.3 million, with a median of $4000.0 recorded in 2024.
  • Peak YoY movement for Net Income: crashed 6574.4% in 2021, then skyrocketed 617775.0% in 2025.
  • A 5-year view of Net Income shows it stood at -$88.8 million in 2021, then surged by 122.32% to $19.8 million in 2022, then crashed by 107.96% to -$1.6 million in 2023, then skyrocketed by 100.25% to $4000.0 in 2024, then surged by 617775.0% to $24.7 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Net Income are $24.7 million (Q4 2025), $4000.0 (Q4 2024), and -$59000.0 (Q3 2024).